AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Rio2, you have to buy into a relatively young, fast-growing producer that is trying to balance aggressive expansion with disciplined execution at both Fenix Gold and Condestable. The MEIA approval at Condestable strengthens the near term story by firming up a decade of environmentally approved mine life and clearing the way for higher throughput and dry stack tailings, which directly supports the recent step-up in earnings and the company’s more diversified copper and gold profile. In the short term, key catalysts remain the ramp-up of Fenix Gold toward steady-state output, completion of Condestable expansion engineering studies, and any updates on TSX approvals and financing tied to Condestable. The biggest risks cluster around execution, permitting follow-through, capital needs and the stock’s rich earnings multiple after a very large multi-year return.
However, there is one project execution risk that recent gains may cause some to overlook. Rio2's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com